Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may forecast which cirrhosis patients survive after discharge

NCT ID NCT06855056

Knowledge-focused Sponsor: European Foundation for Study of Chronic Liver Failure Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers are studying whether certain molecules in the blood can predict how well patients with liver cirrhosis will do after leaving the hospital. The trial enrolls adults aged 18 to 80 who were admitted for a serious complication of cirrhosis, such as fluid buildup, confusion, bleeding, or infection, and who are well enough to go home. By measuring these biomarkers at discharge, the team aims to see if they can forecast survival at three months and identify different recovery paths over six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the biomarkers prove accurate, doctors could one day use a simple blood test to identify which cirrhosis patients face the highest risk after leaving the hospital and tailor their follow-up care.
What could go wrong
This is an observational study, so it cannot prove that acting on biomarker results improves outcomes. The biomarkers may not predict survival reliably in other hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

189 people

The number who actually took part.

Started

Mar 2025

Finished

Sep 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients eligible for this study will be patients with decompensated cirrhosis expected to be discharged from the hospital within 48 hours after an index admission for AD according to the EASL-CLIF criteria.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 and 80 years. 2. Patients with decompensated cirrhosis admitted to hospital due to AD according to the EASL-CLIF criteria (rapid onset of ascites, hepatic encephalopathy, portal hypertensive- related gastrointestinal bleeding, bacterial infection, or any combination of these), including those who presented ACLF during hospitalization. 3. Recovery from AD and expected to be discharged within the next 48 hours. Exclusion Criteria: 1. Admission for planned diagnostic or therapeutic procedures 2. Active malignancy (except for hepatocellular carcinoma within the Milan criteria or nonmelanocytic skin cancer) 3. Antiviral treatment for hepatitis C, B and delta initiated in the last 6 months or planned to be initiated in the following 6 months. 4. HIV positive (except undergoing treatment and who do not exhibit clinical manifestations of AIDS). 5. Ongoing alcohol use disorder with an expected low adherence to prescriptions as judged by physician 6. Previous liver or other organ transplantation 7. Patients with TIPS or other surgical porto-caval shunts 8. Chronic organic renal failure stage IV and V or estimated Glomerular Filtration Rate \<20 ml/min according to the MDRD equations 9. Chronic heart failure NYHA class III or IV 10. Pulmonary disease GOLD III or IV 11. Patients with a history of significant extrahepatic disease with life expectancy \<6 months 12. Severe psychiatric disorders 13. Pregnancy and breast-feeding 14. Expected low adherence to study protocol as judged by physician 15. Patients who cannot provide written informed consent or refuse to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Decompensated cirrhosis of liver are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute-On-Chronic Liver Failure cirrhosis of liver liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Decompensated cirrhosis of liver Liver cirrhosis

Contacts and locations

Locations

  • A.O.U. Città della Salute e della Scienza di Torino

    Torino, 10126, Italy

  • Hospital Beaujon

    Clichy, 92110, France

  • Hospital Clinic de Barcelona

    Barcelona, 08036, Spain

  • Hospital Universitari Vall d'Hebron Research Institute

    Barcelona, 08035, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, 28034, Spain

  • IRCCS Azienda Ospedaliero Universitaria di Bologna Policlinico di S.Orsola

    Bologna, Italia, 40138, Italy

  • Royal Free Hospital

    London, NW3 2QG, United Kingdom

  • University Hospital, Aachen

    Aachen, 52074, Germany

  • Universitätsklinikum Münster

    Münster, 48149, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.